Skip to Content
Merck
CN
All Photos(1)

Documents

1361009

USP

Levodopa

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

3,4-Dihydroxy-L-phenylalanine, 3-(3,4-Dihydroxyphenyl)-L-alanine, L-3-Hydroxytyrosine, L-DOPA, Levodopa

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
(HO)2C6H3CH2CH(NH2)CO2H
CAS Number:
59-92-7
Molecular Weight:
197.19
Beilstein:
2215169
MDL number:
MFCD00002598
UNSPSC Code:
41116107
PubChem Substance ID:
329750042
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

levodopa

manufacturer/tradename

USP

mp

276-278 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O

InChI

1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1

InChI key

WTDRDQBEARUVNC-LURJTMIESA-N

Gene Information

human ... DRD3(1814)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Levodopa USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Carbidopa and Levodopa Tablets
  • Carbidopa and Levodopa Orally Disintegrating Tablets
  • Carbidopa and Levodopa Extended-Release Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302,H315,H319,H335

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Carbidopa and Levodopa Tablets
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 47(5) (2022)
Carbidopa and Levodopa Orally Disintegrating Tablets
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 44(1), 759-759 (2022)
Levodopa
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 40(1), 2604-2604 (2020)
Carbidopa and Levodopa Extended-Release Tablets
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 43(3), 753-753 (2018)
Nicolas Morin et al.
Experimental neurology, 256, 105-116 (2013-01-31)
The treatment of motor symptoms of Parkinson disease (PD) with the dopamine (DA) precursor, l-3,4-dihydroxyphenylalanine (l-DOPA) introduced 50years ago still remains a very effective medication. However, involuntary movements termed l-DOPA-induced dyskinesias (LID) appear in the vast majority of PD patients
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service